Overview

* Compass Therapeutics ( CMPX ) reports Q3 net loss of $14.3 mln, increased R&D expenses

* Company holds $220 mln in cash, providing runway into 2028

* New response observed in CTX-8371 Phase 1 study, no dose-limiting toxicities

Outlook

* Compass expects to report OS and PFS data for tovecimig in late Q1 2026

* CTX-8371 topline data to be presented in H1 2026

* CTX-10726 IND filing planned for Q4 2025

Result Drivers

* INCREASED R&D EXPENSES - R&D expenses increased due to manufacturing and IND-enabling costs related to CTX-10726

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$14.25

Income mln

Q3 Basic -$0.08

EPS

Q3 -$15.81

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Compass Therapeutics Inc. ( CMPX ) is $10.00, about 62.1% above its November 4 closing price of $3.79

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)